Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer sets sights on new obesity drug market in multibillion-dollar acquisition

A little more than five months after Pfizer discontinued development of its weight-loss drug known as danuglipron, the drugmaker announced its plan on Monday to acquire a biopharmaceutical company for close to $5 billion. Pfizer published a press release on Monday confirming the unanimous agreement to acquire Metsera, a "clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic disease…

Pfizer to buy Metsera for $4.9 billion in obesity drug bet

Karen Leigh, Madison Muller and Damian Garde (Bloomberg) — Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value o…

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it’s acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion. In addition to potential future payments tied to specific clinical and regulatory milestones, Pfizer said it will acquire all outstanding shares of Metsera stock fo…

Pfizer splashes $11b to buy weight-loss drugmaker Metsera

Pharma giant Pfizer hopes its purchase of Metsera will consolidate its position in the booming obesity drug sector.